Date of publication: May 23, 2018

News & Views

Preview of ERA-EDTA 2018: CKD-MBD

For this year’s ERA-EDTA congress, the COMPACT RENAL team have not only put together a selection of the highlights relating to mineral bone disease, but are also preparing for the new e-campus being revealed in Copenhagen. The new-look e-campus will showcase the educational tools available on COMPACT RENAL as well as features such as a rare conditions corner, dedicated learning stations, internet access and, of course, refreshments. For more information on the e-campus see the recent news article.

To allow you to plan your time in Copenhagen this article provides a guide to the presentations and posters covering mineral bone disease in chronic kidney disease.

Thursday, May 24th

On the opening day of the congress there is a CME course ‘Emerging insights in CKD-MBD’, organised by the CKD-MBD working group and chaired by Mario Cozzolino, Italy and Marc Vervloet, The Netherlands. The afternoon will include presentations on novel compounds, the status of FGF23 development and the treatment of MBD post-transplant. To obtain CME credits don’t forget to scan your badge as you enter the lecture hall.

Friday, May 25th

The second plenary lecture of the congress will be given by Klaus Olgaard, Denmark, and entitled ‘New paradigms of the kidney – Vascular-bone axis in CKD’. Partaking in the discussion will be the chairs, Bo Feldt-Rasmussen, Denmark and Gérard London, France.

Within the late-breaking clinical trial session will be presentation of data on ferric citrate in advanced chronic kidney disease by Geoffrey Block, USA.

Other sessions of relevance include:

  • Treatment of CKD-MBD’ which will provide a review of the differences in phosphate binders and the use of calcimimetics or vitamin D derivatives, as well as treatment in patients with a kidney graft. Chairs: Mario Cozzolino, Italy; Ewa Lewin, Denmark
  • ‘Bone disease in haemodialysis’, which includes a mini-lecture by Markus Ketteler, Germany on implementing the new CKD-MBD guidelines and a free communication by Angel de Francisco, Spain, of interim data from the VERIFIE study into the use of sucroferric oxyhydroxide (SFOH) for the control of phosphorus in dialysis patients. [FO047]

Posters of interest on Friday include:

  • Late-breaking clinical trial data on the effects of nicotinamide and lanthanum carbonate on serum phosphate and FGF23 concentrations
  • A number of posters featuring real world evidence and other study data on sucroferric oxyhydroxide:
  • Other notable posters report results for cinacalcet; FP613 shows data from the real-world MIMOSA study, while FP605 outlines results from a 5-year follow-up analysis.

Saturday, May 26th

There are several industry symposia of note on Saturday:

  • While primarily focused on Fabry’s disease, the Shire sponsored session ‘Long-term evidence on CKD-MBD – common and uncommon conditions’ also includes a talk by Alastair Hutchison, UK on the experience and long-term safety data for phosphate binders
  • A panel led by Professor Tilman Drüeke, France will present: ‘The evolving face of CKD-MBD: can an increased understanding lead to improvements in treatment?’, sponsored by Vifor Fresenius Medical Care Renal Pharma. The session will highlight the complexity of CKD-MBD and choosing appropriate treatment targets for the management of phosphate levels and SHPT
  • Entitled ‘Targeting intestinal phosphate absorption – A new therapeutic approach for control of hyperphosphataemia’, the Medice sponsored symposium, chaired by Markus Ketteler, Germany, plans to outline the growing understanding of intestinal phosphate absorption, alongside results from the NOPHOS study of nicotinamide.

The Free Communication session, ‘CKD-MBD’, contains three relevant talks:

  • SaO027,analysing the association between changes in bone mineral parameters and mortality
  • SaO029, pilot study of the effect of ferric carboxymaltose on intact FGF23 levels
  • SaO030, 5-year mortality and hospitalisation risk for CKD-MBD in an international cohort

The symposium ‘Cardiovascular calcifications in CKD’ includes two talks of potential interest: ‘Pathophysiology of vascular calcification’ by Mario Cozzolino, Italy, and ‘Calcium sensing receptor and calcimimetics’ by Jordi Bover, Spain.

A collaboration between the ERA-EDTA and theEuropean Society for Paediatric Nephrology (ESPN) has resulted in a joint symposium which will include a presentation by Rukshana Shroff, UK entitled ‘CKD-MBD in paediatric population’.

Posters of interest on Saturday include:

  • SP322 looks at the interaction between FGF23 levels, adiponectin and vitamin D receptor activation
  • SP548 a comparison of phosphate binders and their impact on cardiac valvular calcification
  • SP289 a study to determine factors associated with levels of vascular calcification

Sunday, May 27th

There are no CKD-MBD sessions scheduled for Sunday.

We wish you a safe journey to Copenhagen, and look forward to reporting back on all the key presentations here at

Leave a Reply


You are about to leave

Clicking the "Continue" link below will take you to an external website. Compact Renal is not responsible for the contents of any external website. Compact Renal is providing these links to you as a convenience, and the inclusion of any links does not imply endorsement of the linked site by Compact Renal.

Do you wish to continue?

Continue Cancel